| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 |
| 29 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2026, Cartesian Therapeutics, Inc. (the “Company”) held the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 24,151,536 shares of the Company’s common stock, par value $0.0001 per share (the “common stoc... |
| 09 Jun 2026 |
8-K: Regulation FD Disclosure
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases |
| 26 May 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more
This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of May 22, 2026 (the “Closing Date”) is entered into among CARTESIAN THERAPEUTICS, INC., a Delaware ... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis |
| 30 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 26, 2026, Murat Kalayoglu, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”), notified the Company of his intent to resign from the Board, effective as of March 31, 202... |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis |
| 09 Jan 2026 |
8-K: Regulation FD Disclosure
Pioneering mRNA Cell Therapy for Autoimmunity January 2026 Exhibit 99.1 |
| 18 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to or Waivers of the Code of Ethics +1 more
This Code of Business Conduct and Ethics (the “Code”) contains general guidelines for conducting the business of Cartesian Therapeutics, Inc. (the “Company” or “we”) consistent with the highest standards of business ethics. To the extent... |
| 13 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Pioneering mRNA Cell Therapy for Autoimmunity November 2025 Exhibit 99.2 |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis |
| 30 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
1.1 REGISTERED OFFICE. The registered office of Cartesian Therapeutics, Inc. (the “Corporation”) shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “certificate of incorpor... |
| 21 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 15, 2025, Cartesian Therapeutics, Inc. (the “Company”) eliminated the position of Chief Scientific Officer and delivered a notice of termination of employment without cause to Christopher Jewell, Ph.D., who currently serves as... |
| 08 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 2, 2025, the Board of Directors (the “Board”) of Cartesian Therapeutics, Inc. (the “Company”) appointed June Seymour as the Company’s Chief Accounting Officer, effective upon the commencement of Ms. Seymour’s full-time employm... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis |
| 16 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 13, 2025, Cartesian Therapeutics, Inc. (the “Company”) held the 2025 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 21,868,804 shares of the Company’s common stock, par value $0.0001 per share (the “common stoc... |
| 30 May 2025 |
8-K: Other Events
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial |
Loading...